"A Change is Gonna Come" to Treatment of Lupus Nephritis: A Review. (PubMed, Am J Kidney Dis) - Nov 15, 2025 - "Glucocorticoids with cytotoxic agents or mycophenolate mofetil (MMF) remain the standard of care, but newer therapies targeting B cells (e.g., belimumab, obinutuzumab) and T cells (e.g., voclosporin) have proven efficacy as add-on treatments. Novel therapies such as complement and cytokine inhibitors are being evaluated in preclinical and clinical trials. While maintenance therapy with MMF remains the standard, the distinction between sequential induction and maintenance therapy has increasingly blurred, and new strategies to reduce long term disease and pharmacologic toxicity to improve remission and relapse rates are emerging."
Journal • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
Casey Gashti; Niraj B Desai; William L Whittier
|